Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies☆
References (37)
Epidemiology of coronary heart disease: The Framingham study
Am J Med
(1984)- et al.
Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia
Lancet
(1981) - et al.
Comparison of selectivity of LDL removal by double filtration and dextran-sulfate cellulose column plasma pheresis
Atherosclerosis
(1986) - et al.
Separation of apolipoprotein B subfractions by high performance gel permeation chromatography
Clin Chim Acta
(1986) - et al.
Short- and long-term experience in the treatment of severe hypercholesterolemia by extracorporeal heparin induced LDL precipitation
Curr Ther Res
(1992) Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease
JAMA
(1984)Coronary Primary Prevention Trial Results: II. The relationship of reduction of incidence of coronary heart disease to cholesterol lowering
JAMA
(1984)- et al.
Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA
(1986) Familial hypobetalipoproteinemia and familial defective apolipoprotein B 100: Genetic disorders associated with apolipoprotein B
Curr Opin Lipid
(1990)- et al.
Assessment of long-term plasma exchange for familial hypercholesterolemia
Br Heart J
(1980)
Plasma-exchange therapy of homozygous familial hypercholesterolemia
N Engl J Med
Regression der Koronarsklerose bei familiärer Hypercholesterinämie IIa durch spezifische LDL-Apherese
Dtsch Med Wochenschr
Treatment of familial hypercholesterolemia by means of specific immunoadsorption
J Clin Apheresis
Selective removal of low density lipoproteins by plasmapheresis in familial hypercholesterolemia
Arteriosclerosis
Selective removal of low density lipoproteins (LDL) by precipitation at low pH: First clinical application of the HELP system
Klin Wochenschr
The HELP-LDL-Apheresis Multicentre Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months
Eur J Clin Invest
Die Behandlung der familiären Hypercholesterinämie Typ IIa mit Membran-LDL-Apherese. Technik und Langzeit-Ergebnisse
Nieren Hochdruckkrankheiten
A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity
Clin Chim Acta
Cited by (92)
One-step engineering dual-network reinforced hydrogel microspheres with excellent anti-coagulant and low-density lipoprotein removal
2024, Separation and Purification TechnologySimple emulsion template method towards self-anticoagulant and high-efficiency carboxymethyl chitosan-based adsorbent for low-density lipoprotein from whole blood
2023, Journal of Colloid and Interface ScienceCitation Excerpt :Most relevant researches have focused on modifying the functional groups on substrates of adsorbents. According to adsorption principles and ligands, the currently available LDL adsorbents can be divided into immunosorbent [10], anionic sorbent [11,12], hydrophobic sorbent [13] and amphiphilic sorbent [14]. As a research hotspot and frontier trend, anionic adsorbents can selectively bind the positively charged apolipoprotein B100 by their negatively charged groups [15].
Lipoprotein Apheresis
2016, Endocrinology and Metabolism Clinics of North AmericaLipoprotein Apheresis
2015, Cardiology ClinicsCitation Excerpt :The mechanism by which LA acutely lowers HDL-C (10%–20%) is not fully understood because, unlike apoB lipoproteins, the HDL-C is negative charged. Some explanations involve filtration, hemodilution, activation of hepatic triglyceride lipase (HTGL), or the decreased activity of lecithin-cholesterol acyltransferase.29 Several studies30,31 of LA therapy have revealed a greater acute reduction of total HDL than apolipoprotein A-I, the primary HDL lipoprotein involved in reverse cholesterol transport, and that most of the HDL-C removed following LA is a proinflammatory type, as measured by the inability of HDL to inhibit LDL-induced monocyte chemotactic activity.32,33
Current situation of lipoprotein apheresis in Saxony
2013, Atherosclerosis SupplementsCitation Excerpt :Additionally, it compares the efficiency of the LA treatment at the UHD with that at other centers. Six lipoprotein apheresis methods were used, for details about these methods see the literature [4–10] (Table 1). In 2010, 119 patients were treated with lipoprotein apheresis in Saxony (Table 2), more than half of them at the UHD Apheresis Center.
- ☆
Supported by a grant from the Bundesminister für Forschung und Technologie (BMFT 01ZJ85014).